Amgen vs Burlington: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Amgen and Burlington side by side

1. 1972Burlington

   Burlington Coat Factory opens

   Monroe Milstein bought a coat outlet in a former factory building in Burlington, New Jersey, and sold brand-name coats at discount prices, the start of Burlington Coat Factory.

2. 1980Amgen

   Applied Molecular Genetics is incorporated

   Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.

3. 1983Amgen

   Nasdaq listing and the erythropoietin clone

   Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.

4. 1983Burlington

   First public offering

   Burlington Coat Factory Warehouse Corporation went public for the first time, funding expansion from a regional discounter into a national chain with year-round apparel, shoes, baby and home departments.

5. 1984Amgen

   Kirin-Amgen joint venture formed

   Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.

6. 1985Amgen

   G-CSF cloned, leading to Neupogen

   While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.

7. 1989Amgen

   FDA approves Epogen

   The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.

8. 1989Burlington

   Cohoes Specialty Stores acquired

   Burlington bought the Cohoes Specialty Stores off-price chain from upstate New York, including a 50 percent stake in the Cohoes Commons building; a few stores still traded as Cohoes Fashions decades later.

9. 1991Amgen

   Neupogen approved, giving Amgen a second franchise

   The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.

10. 1991Amgen

    Amgen wins the erythropoietin patent fight

    On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.

11. 2001Amgen

    FDA approves Aranesp, the longer-acting EPO

    Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.

12. 2002Amgen

    US$16 billion Immunex acquisition brings Enbrel in-house

    Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.

13. 2006Burlington

    Bain Capital takes Burlington private

    Bain Capital acquired Burlington Coat Factory for about $2.06 billion, ending 34 years of Milstein family control. Long-time executive Mark Nesci became chief executive.

14. 2008Burlington

    Tom Kingsbury named CEO

    Former Kohl's executive Thomas Kingsbury became president and CEO in December 2008, succeeding Mark Nesci, and began overhauling buying, inventory management and the supply chain.

15. 2010Amgen

    Prolia and XGEVA create the bone health franchise

    The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.

16. 2013Burlington

    Return to the stock market

    Burlington Stores priced its IPO on October 2, 2013, selling 13.3 million shares at $17 each for about $226 million, and listed under the ticker BURL.

17. 2019Amgen

    US$13.4 billion purchase of Otezla from Celgene

    Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.

18. 2019Burlington

    Michael O'Sullivan becomes CEO

    Former Ross Stores president and COO Michael O'Sullivan succeeded Tom Kingsbury as CEO around September 16, 2019, and later launched the Burlington 2.0 plan of leaner inventories and smaller stores.

19. 2020Amgen

    Amgen joins the Dow Jones Industrial Average

    Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.

20. 2020Burlington

    Online sales end and stores close for the pandemic

    On March 5, 2020, Burlington said it would shut its e-commerce business. Days later pandemic lockdowns closed its stores, and fiscal 2020 revenue fell to $5.76 billion with a $216.5 million net loss.

21. 2023Amgen

    US$27.8 billion Horizon Therapeutics acquisition closes

    Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.

22. 2023Burlington

    Bed Bath & Beyond leases

    Burlington won 44 Bed Bath & Beyond leases for $12 million at the June 2023 bankruptcy auction, the largest share of the 109 sold, and later reported 62 former Bed Bath & Beyond leases in total.

23. 2024Amgen

    Imdelltra becomes the first T-cell engager for small cell lung cancer

    The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.

24. 2025Amgen

    VESALIUS-CV extends the Repatha case to primary prevention

    In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.

25. 2025Burlington

    Joann leases

    After Joann's second bankruptcy, Burlington agreed in April 2025 to take over 45 Joann store leases, many of which became part of its fiscal 2026 opening program.

26. 2026Amgen

    Medicare price setting reaches Enbrel and Otezla

    Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.

27. 2026Burlington

    Record fiscal 2025 results

    Burlington reported fiscal 2025 total revenue of $11.57 billion and net income of $610.2 million, and ended the year on January 31, 2026, with 1,212 stores.

28. 2026Burlington

    Tariff refunds put into prices

    In the second quarter of fiscal 2026, sales rose 11 percent to $2.998 billion. Burlington received $55 million in tariff refunds and said it would reinvest them in lower prices; the store count reached 1,287.

29. 2026Burlington

    Headquarters move to Philadelphia announced

    On September 3, 2026, Burlington said it will invest $370 million to move its headquarters from Burlington Township, New Jersey, to Schuylkill Yards in Philadelphia, in phases from late 2028 or early 2029.

Acquisitions

Questions about Amgen vs Burlington